Your browser is no longer supported. Please, upgrade your browser.
Settings
EYEN [NASD]
Eyenovia, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own20.40% Shs Outstand24.81M Perf Week-4.35%
Market Cap140.91M Forward P/E- EPS next Y-0.70 Insider Trans0.75% Shs Float15.61M Perf Month-8.94%
Income-19.80M PEG- EPS next Q-0.22 Inst Own7.70% Short Float0.84% Perf Quarter-20.98%
Sales2.00M P/S70.45 EPS this Y36.30% Inst Trans9.67% Short Ratio0.93 Perf Half Y62.24%
Book/sh0.62 P/B8.87 EPS next Y16.70% ROA-91.90% Target Price- Perf Year102.95%
Cash/sh1.11 P/C4.96 EPS next 5Y- ROE-144.80% 52W Range2.55 - 7.72 Perf YTD-9.24%
Dividend- P/FCF- EPS past 5Y-16.90% ROI-125.20% 52W High-28.76% Beta-
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin60.00% 52W Low115.68% ATR0.41
Employees31 Current Ratio1.80 Sales Q/Q- Oper. Margin- RSI (14)44.73 Volatility7.06% 7.11%
OptionableYes Debt/Eq0.03 EPS Q/Q44.60% Profit Margin- Rel Volume0.65 Prev Close5.36
ShortableYes LT Debt/Eq0.03 EarningsMar 25 AMC Payout- Avg Volume141.58K Price5.50
Recom1.70 SMA20-3.81% SMA50-10.06% SMA20021.52% Volume92,075 Change2.61%
Mar-01-21Initiated Northland Capital Outperform $10
Feb-03-20Downgrade Oppenheimer Outperform → Perform
Apr-01-21 07:30AM  
Mar-25-21 04:05PM  
02:30PM  
Mar-23-21 07:30AM  
Mar-18-21 08:00AM  
Mar-17-21 08:00AM  
Mar-10-21 08:00AM  
Mar-08-21 12:24AM  
Mar-02-21 07:30AM  
Feb-16-21 08:00AM  
Jan-26-21 07:30AM  
Jan-06-21 08:00AM  
Dec-29-20 07:00AM  
Dec-16-20 07:00AM  
Dec-08-20 01:23AM  
Dec-03-20 07:00AM  
Dec-02-20 07:07PM  
Nov-10-20 04:06PM  
02:45PM  
Nov-09-20 03:30PM  
Nov-05-20 08:00AM  
Oct-13-20 03:40PM  
07:00AM  
Oct-12-20 07:00AM  
Oct-05-20 07:00AM  
Sep-09-20 08:30AM  
Aug-26-20 07:31AM  
Aug-24-20 08:30AM  
Aug-21-20 04:05PM  
Aug-19-20 09:10AM  
Aug-18-20 04:03PM  
Aug-12-20 04:05PM  
07:29AM  
Aug-11-20 08:00AM  
Jul-29-20 08:30AM  
Jul-20-20 03:30PM  
Jun-30-20 04:05PM  
Jun-11-20 04:10PM  
Jun-05-20 04:10PM  
May-13-20 04:05PM  
May-06-20 08:30AM  
Apr-22-20 10:10AM  
Mar-26-20 06:31AM  
Mar-25-20 04:05PM  
02:30PM  
Mar-24-20 05:10PM  
Mar-23-20 06:35PM  
Mar-11-20 08:30AM  
Mar-04-20 08:30AM  
Feb-17-20 07:33AM  
Feb-10-20 09:25AM  
Dec-19-19 09:55AM  
08:30AM  
Dec-02-19 09:02AM  
Nov-27-19 09:00AM  
Nov-13-19 04:05PM  
Nov-12-19 10:42AM  
08:23AM  
Nov-11-19 11:24AM  
09:42AM  
07:50AM  
Nov-07-19 11:15AM  
10:32AM  
Nov-06-19 09:56AM  
Nov-05-19 11:50AM  
11:24AM  
11:13AM  
Nov-04-19 11:42AM  
10:56AM  
10:49AM  
10:22AM  
10:01AM  
09:10AM  
Oct-31-19 10:47AM  
08:30AM  
Oct-30-19 07:01AM  
Oct-29-19 04:05PM  
Oct-02-19 08:30AM  
Sep-19-19 12:07PM  
Sep-03-19 08:30AM  
Aug-12-19 02:30PM  
Aug-06-19 08:30AM  
Jul-16-19 04:05PM  
Jul-15-19 07:15PM  
04:30PM  
Jul-11-19 11:13AM  
09:00AM  
Jul-10-19 04:07PM  
Jun-04-19 08:30AM  
May-14-19 06:30AM  
May-06-19 10:53AM  
May-01-19 08:30AM  
Mar-27-19 06:30AM  
Mar-13-19 08:30AM  
Mar-04-19 08:30AM  
Feb-25-19 08:30AM  
Feb-13-19 08:30AM  
Feb-06-19 08:30AM  
Feb-05-19 08:00AM  
Jan-31-19 08:30AM  
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. The company focuses on to develop clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its pipelines focus on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates in pipeline include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grant Stuart M.10% OwnerMar 05Buy5.5035,000192,5004,254,748Mar 08 05:34 PM
GANDOLFO JOHN PChief Financial OfficerNov 19Buy3.404,00013,6006,000Nov 23 04:05 PM
Grant Stuart M.10% OwnerOct 12Buy3.55100,000355,0004,219,748Oct 13 11:54 AM
Grant Stuart M.10% OwnerSep 24Buy2.9975,000224,5004,119,748Sep 25 01:42 PM
Clasby Jennifer GVP, Clinical OperationsSep 18Option Exercise1.9526,73752,13755,702Oct 16 05:04 PM
Grant Stuart M.10% OwnerAug 20Buy2.06451,620929,4344,044,748Aug 24 06:05 AM
Grant Stuart M.10% OwnerAug 19Buy3.60333,0001,198,8003,593,128Aug 24 06:05 AM